MedTrace Logo

Effects of Spironolactone on Matrix Metalloproteinases (MMPs) in Heart Failure

NCT00663195 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2008-04-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effects of spironolactone on circulating MMP levels and insulin resistance in patients with chronic heart failure.

Conditions

  • Chronic Stable Heart Failure

Interventions

DRUG

spironolactone + furosemide

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks

Sponsors & Collaborators

  • Tottori University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-01-31
Completion
2005-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00663195 on ClinicalTrials.gov